Generic Semaglutide Spreads: The Hims & Hers Canada Signal

TL;DR: Hims & Hers just launched generic semaglutide in Canada for about $107 USD a month — a fraction of US branded prices — after Novo Nordisk lost its Canadian patent. It is a preview of where cheaper access is heading, and a useful reminder of why the US is not there yet.

If you have watched US GLP-1 prices and wondered when the cheaper version arrives, a story unfolding just across the northern border is worth your attention. It says a lot about how the next phase of access plays out — and about how long the wait may still be where you live.

What just happened

Hims & Hers launched a generic semaglutide offering in Canada, with personalized care plans that can include generic semaglutide starting at CAD 149 — about $107 USD — per month. For context, branded Ozempic and Wegovy in the US carry list prices well over $1,000 a month before insurance or savings programs.

The opening came from an unusual place: Novo Nordisk lost its Canadian patent protection on its semaglutide drugs after failing to pay a small maintenance fee. That administrative slip let generic manufacturers in years earlier than they could have otherwise — and gave a telehealth platform the room to price aggressively.

"Bringing generic semaglutide to the market means more Canadians have real and affordable access to this treatment," said Austin Kouri, managing director at Hims & Hers Canada. "When patients have options and costs come down, everyone benefits."

Why the US is a different story

It is tempting to read this as "cheap semaglutide is coming." For Canada, it has arrived. For the United States, the picture is more guarded.

US semaglutide patents are expected to hold into the early 2030s, which is the single biggest reason a true generic is not on American shelves yet. The compounded-semaglutide path that filled the gap during the shortage has narrowed sharply now that the FDA considers the shortage resolved, and the regulatory questions around compounding are still being worked out. In the US, the relationship between Novo Nordisk and Hims has actually moved the other direction: after a patent dispute, the two announced a partnership for Hims to sell branded Ozempic and Wegovy directly — a very different model from underselling them with a generic.

So the Canadian launch is best read as a signal, not a schedule. It shows what post-patent pricing looks like when generics are allowed to compete — roughly a tenth of the branded list price. It does not mean that price is coming to the US on the same timeline.

What to do with this if you are in the US

The honest answer for most US readers is: not much changes today, but it is worth understanding the landscape so you can make good decisions as it shifts.

A few things stay true regardless of where prices land. The drug works while you take it, and the hardest part of the journey is rarely the first month — it is staying on long enough, through cost changes and supply wobbles, for the change to hold. Cheaper access helps people start; it does not, on its own, help them stay. That part is still about what you build around the medication.

If cost is the thing standing between you and starting or staying, it is worth mapping your real options before assuming you are priced out. We track where GLP-1 prices are actually moving in 2026 and what generic access realistically looks like, and our cost calculator compares the paths — branded, savings card, cash-pay — side by side so the number you are working with is the real one, not the scary headline one.

Canada got a head start by accident. The rest of the access story is still being written — and worth watching.

This article covers GLP-1 access and pricing. It is not medical advice. For questions about your own medication, talk to your prescriber.

Sources

1. Hims & Hers launches generic semaglutide in Canada (MobiHealthNews): https://www.mobihealthnews.com/news/hims-hers-launches-generic-semaglutide-offering-canada